Literature DB >> 22525702

Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.

Suparna Mazumder1, Gaurav S Choudhary, Sayer Al-Harbi, Alexandru Almasan.   

Abstract

ABT-737 is a small molecule Bcl-2 homology (BH)-3 domain mimetic that binds to the Bcl-2 family proteins Bcl-2 and Bcl-xL and is currently under investigation in the clinic. In this study, we investigated potential mechanisms of resistance to ABT-737 in leukemia cell lines. Compared with parental cells, cells that have developed acquired resistance to ABT-737 showed increased expression of Mcl-1 in addition to posttranslational modifications that facilitated both Mcl-1 stabilization and its interaction with the BH3-only protein Bim. To sensitize resistant cells, Mcl-1 was targeted by two pan-Bcl-2 family inhibitors, obatoclax and gossypol. Although gossypol was effective only in resistant cells, obatoclax induced cell death in both parental and ABT-737-resistant cells. NOXA levels were increased substantially by treatment with gossypol and its expression was critical for the gossypol response. Mechanistically, the newly generated NOXA interacted with Mcl-1 and displaced Bim from the Mcl-1/Bim complex, freeing Bim to trigger the mitochondrial apoptotic pathway. Together, our findings indicate that NOXA and Mcl-1 are critical determinants for gossypol-mediated cell death in ABT-737-resistant cells. These data therefore reveal novel insight into mechanisms of acquired resistance to ABT-737.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22525702      PMCID: PMC3377792          DOI: 10.1158/0008-5472.CAN-11-4106

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain.

Authors:  J Bae; C P Leo; S Y Hsu; A J Hsueh
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

2.  Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage.

Authors:  Jorg Michels; Jason W O'Neill; Claire L Dallman; Amalia Mouzakiti; Fay Habens; Matthew Brimmell; Kam Y J Zhang; Ruth W Craig; Eric G Marcusson; Peter W M Johnson; Graham Packham
Journal:  Oncogene       Date:  2004-06-17       Impact factor: 9.867

3.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Authors:  Anthony Letai; Michael C Bassik; Loren D Walensky; Mia D Sorcinelli; Solly Weiler; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

4.  Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.

Authors:  Brian J Tunquist; Richard D Woessner; Duncan H Walker
Journal:  Mol Cancer Ther       Date:  2010-06-22       Impact factor: 6.261

5.  From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia.

Authors:  Loren D Walensky
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

6.  Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

Authors:  Alejo A Morales; Metin Kurtoglu; Shannon M Matulis; Jiangxia Liu; David Siefker; Delia M Gutman; Jonathan L Kaufman; Kelvin P Lee; Sagar Lonial; Lawrence H Boise
Journal:  Blood       Date:  2011-06-09       Impact factor: 22.113

7.  Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers.

Authors:  A R Safa; C J Glover; J L Sewell; M B Meyers; J L Biedler; R L Felsted
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

8.  Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.

Authors:  Noopur Raje; Shaji Kumar; Teru Hideshima; Aldo Roccaro; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Dharminder Chauhan; Nikhil C Munshi; Simon R Green; Kenneth C Anderson
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

9.  Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1.

Authors:  Shogo Kobayashi; Sun-Hee Lee; Xue W Meng; Justin L Mott; Steven F Bronk; Nathan W Werneburg; Ruth W Craig; Scott H Kaufmann; Gregory J Gores
Journal:  J Biol Chem       Date:  2007-04-25       Impact factor: 5.157

Review 10.  Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.

Authors:  M Vogler; D Dinsdale; M J S Dyer; G M Cohen
Journal:  Cell Death Differ       Date:  2008-09-19       Impact factor: 15.828

View more
  56 in total

Review 1.  Pathways and mechanisms of venetoclax resistance.

Authors:  Prithviraj Bose; Varsha Gandhi; Marina Konopleva
Journal:  Leuk Lymphoma       Date:  2017-01-31

2.  MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.

Authors:  Xinghua Wei; Ping Zhou; Xuanting Lin; Yurong Lin; Sifeng Wu; Pengfei Diao; Haiqing Xie; Keji Xie; Ping Tang
Journal:  Tumour Biol       Date:  2014-07-17

3.  The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.

Authors:  M Larrayoz; S J Blakemore; R C Dobson; M D Blunt; M J J Rose-Zerilli; R Walewska; A Duncombe; D Oscier; K Koide; F Forconi; G Packham; M Yoshida; M S Cragg; J C Strefford; A J Steele
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

Review 4.  Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.

Authors:  Bruno Christian Koehler; Dirk Jäger; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 5.  Noxa in rheumatic diseases: present understanding and future impact.

Authors:  Karissa E Cottier; Elise M Fogle; David A Fox; Salahuddin Ahmed
Journal:  Rheumatology (Oxford)       Date:  2013-12-17       Impact factor: 7.580

Review 6.  Why anti-Bcl-2 clinical trials fail: a solution.

Authors:  Y Harazono; K Nakajima; A Raz
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

Review 7.  Biomarkers of therapeutic response to BCL2 antagonists in cancer.

Authors:  Lloyd T Lam; Haichao Zhang; Brenda Chyla
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

8.  Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.

Authors:  Michelle M Williams; Linus Lee; Donna J Hicks; Meghan M Joly; David Elion; Bushra Rahman; Courtney McKernan; Violeta Sanchez; Justin M Balko; Thomas Stricker; Monica Valeria Estrada; Rebecca S Cook
Journal:  Mol Cancer Res       Date:  2016-12-30       Impact factor: 5.852

9.  Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.

Authors:  Joachim C Mertens; Christian D Fingas; John D Christensen; Rory L Smoot; Steven F Bronk; Nathan W Werneburg; Michael P Gustafson; Allan B Dietz; Lewis R Roberts; Alphonse E Sirica; Gregory J Gores
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

10.  Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.

Authors:  David L Hermanson; Sonia G Das; Yunfang Li; Chengguo Xing
Journal:  Mol Pharmacol       Date:  2013-05-21       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.